CoChat
Sign Up
Cited by 2,251Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsAmyotrophic Lateral Sclerosis Research

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Tau in physiology and pathology

Wang, Yipeng, Mandelkow, Eckhard·2016·Nature Reviews Neuroscience
DOI 10.1038/nrn.2015.1
Open this paper in CoChat — free account

Abstract

Tau is a microtubule-associated protein that has a role in stabilizing neuronal microtubules and thus in promoting axonal outgrowth. Structurally, tau is a natively unfolded protein, is highly soluble and shows little tendency for aggregation. However, tau aggregation is characteristic of several neurodegenerative diseases known as tauopathies. The mechanisms underlying tau pathology and tau-mediated neurodegeneration are debated, but considerable progress has been made in the field of tau research in recent years, including the identification of new physiological roles for tau in the brain. Here, we review the expression, post-translational modifications and functions of tau in physiology and in pathophysiology.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrn.2015.1

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 61 references

Research works printed but not linked: 165

  1. Weingarten, M. D., Lockwood, A. H., Hwo, S. Y. & Kirschner, M. W. A protein factor essential for microtubule assembly. Proc. Natl Acad. Sci. USA 72, 1858–1862 (1975). This study led to the discovery of tau protein as a microtubule-associated protein. · DOI · Paper page
  2. Alzheimer, A. Über eine eigenartige Erkrankung der Hirnrinde. Allg. Z. Psychiatrie Psychisch-gerichtl. Med. 64, 146–148 (in German) (1907). Original description of the pathology of 'Alzheimer disease'.
  3. Roberson, E. D. et al. Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 316, 750–754 (2007). This study demonstrates in a mouse model that tau is necessary for Aβ-induced excitotoxicity. · DOI · Paper page
  4. Yoshiyama, Y., Lee, V. M. & Trojanowski, J. Q. Therapeutic strategies for tau mediated neurodegeneration. J. Neurol. Neurosurg. Psychiatry 84, 784–795 (2013). · DOI
  5. Andreadis, A. Misregulation of tau alternative splicing in neurodegeneration and dementia. Prog. Mol. Subcell. Biol. 44, 89–107 (2006). · DOI
  6. LoPresti, P., Szuchet, S., Papasozomenos, S. C., Zinkowski, R. P. & Binder, L. I. Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes. Proc. Natl Acad. Sci. USA 92, 10369–10373 (1995). · DOI · Paper page
  7. Lee, G., Cowan, N. & Kirschner, M. The primary structure and heterogeneity of tau protein from mouse brain. Science 239, 285–288 (1988). This was the first study to sequence tau protein, highlighting its hydrophilic nature and the presence of pseudorepeats. · DOI
  8. Dickson, D. W., Kouri, N., Murray, M. E. & Josephs, K. A. Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J. Mol. Neurosci. 45, 384–389 (2011). · DOI · Paper page
  9. Orozco, D. et al. Loss of fused in sarcoma (FUS) promotes pathological Tau splicing. EMBO Rep. 13, 759–764 (2012). · DOI
  10. Smith, P. Y. et al. MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy. Hum. Mol. Genet. 20, 4016–4024 (2011). · DOI · Paper page
  11. Santa-Maria, I. et al. Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau. J. Clin. Invest. 125, 681–686 (2015). · DOI · Paper page
  12. Moschner, K. et al. RNA protein granules modulate tau isoform expression and induce neuronal sprouting. J. Biol. Chem. 289, 16814–16825 (2014). · DOI
  13. Bruch, J., Xu, H., De Andrade, A. & Hoglinger, G. Mitochondrial complex 1 inhibition increases 4-repeat isoform tau by SRSF2 upregulation. PLoS ONE 9, e113070 (2014). · DOI
  14. Kampers, T., Friedhoff, P., Biernat, J., Mandelkow, E. M. & Mandelkow, E. RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett. 399, 344–349 (1996). · DOI · Paper page
  15. Violet, M. et al. A major role for Tau in neuronal DNA and RNA protection in vivo under physiological and hyperthermic conditions. Front. Cell Neurosci. 8, 84 (2014). · DOI · Paper page
  16. Chen, J., Kanai, Y., Cowan, N. J. & Hirokawa, N. Projection domains of MAP2 and tau determine spacings between microtubules in dendrites and axons. Nature 360, 674–677 (1992). · DOI · Paper page
  17. Frappier, T. F., Georgieff, I. S., Brown, K. & Shelanski, M. L. τ regulation of microtubule-microtubule spacing and bundling. J. Neurochem. 63, 2288–2294 (1994). · DOI · Paper page
  18. Liu, C. & Gotz, J. Profiling murine tau with 0N, 1N and 2N isoform-specific antibodies in brain and peripheral organs reveals distinct subcellular localization, with the 1N isoform being enriched in the nucleus. PLoS ONE 8, e84849 (2013). · DOI
  19. Kosik, K. S., Orecchio, L. D., Bakalis, S. & Neve, R. L. Developmentally regulated expression of specific tau sequences. Neuron 2, 1389–1397 (1989). · DOI
  20. Takuma, H., Arawaka, S. & Mori, H. Isoforms changes of tau protein during development in various species. Brain Res. Dev. Brain Res. 142, 121–127 (2003). · DOI
  21. Llorens-Martin, M. et al. Tau isoform with three microtubule binding domains is a marker of new axons generated from the subgranular zone in the hippocampal dentate gyrus: implications for Alzheimer's disease. J. Alzheimers Dis. 29, 921–930 (2012). · DOI
  22. Goedert, M., Wischik, C. M., Crowther, R. A., Walker, J. E. & Klug, A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc. Natl Acad. Sci. USA 85, 4051–4055 (1988). This paper reveals the sequence of human tau protein and its presence in the core of tau filaments. · DOI · Paper page
  23. Adams, S. J. et al. Overexpression of wild-type murine tau results in progressive tauopathy and neurodegeneration. Am. J. Pathol. 175, 1598–1609 (2009). · DOI
  24. Lee, G., Newman, S. T., Gard, D. L., Band, H. & Panchamoorthy, G. Tau interacts with src-family non-receptor tyrosine kinases. J. Cell Sci. 111, 3167–3177 (1998). · DOI
  25. Ittner, L. M. et al. Dendritic function of tau mediates amyloid-β toxicity in Alzheimer's disease mouse models. Cell 142, 387–397 (2010). This paper shows that dendritic tau plays a part in mediating Aβ-induced hyperexcitotoxicity, by regulating the synaptic distribution of FYN. · DOI · Paper page
  26. Brion, J. P., Passareiro, H., Nunez, J. & Flament-Durand, J. Mise en evidence immunologique de la proteine tau au nivea u des lesions de degenerescence neurofibrillaire de la maladie d'Alzheimer. Arch. Biol. (Bruxelles) 95, 229–235 (in French) (1985). This study provided the first evidence that NFTs in the AD brain contain tau protein.
  27. Grundke-Iqbal, I. et al. Abnormal phosphorylation of the microtubule-associated protein τ (tau) in Alzheimer cytoskeletal pathology. Proc. Natl Acad. Sci. USA 83, 4913–4917 (1986). This study demonstrates that tau protein is present in AD NFTs in a hyperphosphorylated state. · DOI · Paper page
  28. Kadavath, H. et al. Tau stabilizes microtubules by binding at the interface between tubulin heterodimers. Proc. Natl Acad. Sci. USA 112, 7501–7506 (2015). This paper found that tau binds at the interface between α-tubulin–β-tubulin heterodimers through residues including the motifs that are essential for the pathological aggregation of tau, suggesting that there is competition between physiological interaction and pathogenic misfolding. · DOI · Paper page
  29. Gruning, C. S. et al. Alternative conformations of the Tau repeat domain in complex with an engineered binding protein. J. Biol. Chem. 289, 23209–23218 (2014). · DOI
  30. Jeganathan, S., von Bergen, M., Brutlach, H., Steinhoff, H. J. & Mandelkow, E. Global hairpin folding of tau in solution. Biochemistry 45, 2283–2293 (2006). · DOI · Paper page
  31. Wischik, C. M. et al. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc. Natl Acad. Sci. USA 85, 4506–4510 (1988). · DOI · Paper page
  32. Wegmann, S., Medalsy, I. D., Mandelkow, E. & Muller, D. J. The fuzzy coat of pathological human Tau fibrils is a two-layered polyelectrolyte brush. Proc. Natl Acad. Sci. USA 110, E313–E321 (2013). · DOI
  33. Kanemaru, K., Takio, K., Miura, R., Titani, K. & Ihara, Y. Fetal-type phosphorylation of the tau in paired helical filaments. J. Neurochem. 58, 1667–1675 (1992). · DOI
  34. Matsuo, E. S. et al. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron 13, 989–1002 (1994). This paper reveals that the post-mortem delay can cause the dephosphorylation of tau by phosphatases, leading to underestimation of the phosphorylation level of tau in vivo , and shows that tau is physiologically phosphorylated at many of the same sites that are phosphorylated in PHF-tau. · DOI
  35. Morris, M. et al. Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat. Neurosci. 18, 1183–1189 (2015). · DOI · Paper page
  36. Hanger, D. P., Anderton, B. H. & Noble, W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 15, 112–119 (2009). · DOI · Paper page
  37. Rosseels, J. et al. Tau monoclonal antibody generation based on humanized yeast models: impact on Tau oligomerization and diagnostics. J. Biol. Chem. 290, 4059–4074 (2015). · DOI
  38. Vega, I. E. et al. Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates. Brain Res. Mol. Brain Res. 138, 135–144 (2005). · DOI
  39. Gong, C. X., Singh, T. J., Grundke-Iqbal, I. & Iqbal, K. Phosphoprotein phosphatase activities in Alzheimer disease brain. J. Neurochem. 61, 921–927 (1993). · DOI · Paper page
  40. Chen, S., Li, B., Grundke-Iqbal, I. & Iqbal, K. IPP2A1 affects tau phosphorylation via association with the catalytic subunit of protein phosphatase 2A. J. Biol. Chem. 283, 10513–10521 (2008). · DOI
  41. Sontag, E. et al. Downregulation of protein phosphatase 2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis. J. Neuropathol. Exp. Neurol. 63, 1080–1091 (2004). · DOI
  42. Planel, E. et al. Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease. J. Neurosci. 24, 2401–2411 (2004). · DOI
  43. Planel, E. et al. Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J. Neurosci. 27, 3090–3097 (2007). This paper shows that anaesthesia can cause tau hyperphosphorylation owing to inhibition of phosphatase activity by hypothermia. · DOI
  44. Kondo, A. et al. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature 523, 431–436 (2015). · DOI · Paper page
  45. Hoover, B. R. et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68, 1067–1081 (2010). This study shows that the hyperphosphorylation of tau drives its entry into postsynaptic terminals, resulting in synaptic dysfunction. · DOI · Paper page
  46. Thies, E. & Mandelkow, E. M. Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J. Neurosci. 27, 2896–2907 (2007). This study demonstrates that missorting of phosphorylated tau into dendrites and spines leads to transport inhibition and loss of spines. · DOI · Paper page
  47. Guillozet-Bongaarts, A. L. et al. Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo. J. Neurochem. 97, 1005–1014 (2006). · DOI
  48. Ittner, L. M., Ke, Y. D. & Gotz, J. Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease. J. Biol. Chem. 284, 20909–20916 (2009). · DOI
  49. Bhaskar, K., Yen, S. H. & Lee, G. Disease-related modifications in tau affect the interaction between Fyn and Tau. J. Biol. Chem. 280, 35119–35125 (2005). · DOI
  50. Reynolds, C. H. et al. Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cγ1, Grb2, and Src family kinases. J. Biol. Chem. 283, 18177–18186 (2008). · DOI
  51. Cook, C. et al. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum. Mol. Genet. 23, 104–116 (2014). · DOI
  52. Cohen, T. J., Friedmann, D., Hwang, A. W., Marmorstein, R. & Lee, V. M. The microtubule-associated tau protein has intrinsic acetyltransferase activity. Nat. Struct. Mol. Biol. 20, 756–762 (2013). · DOI · Paper page
  53. Martin, L., Latypova, X. & Terro, F. Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochem. Int. 58, 458–471 (2011). · DOI
  54. Wang, J. Z., Grundke-Iqbal, I. & Iqbal, K. Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer's disease. Nat. Med. 2, 871–875 (1996). · DOI · Paper page
  55. Liu, F., Zaidi, T., Iqbal, K., Grundke-Iqbal, I. & Gong, C. X. Aberrant glycosylation modulates phosphorylation of tau by protein kinase A and dephosphorylation of tau by protein phosphatase 2A and 5. Neuroscience 115, 829–837 (2002). · DOI
  56. Yuzwa, S. A., Cheung, A. H., Okon, M., McIntosh, L. P. & Vocadlo, D. J. O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers. J. Mol. Biol. 426, 1736–1752 (2014). · DOI
  57. Yan, S. D. et al. Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide. Nat. Med. 1, 693–699 (1995). · DOI · Paper page
  58. Watanabe, A. et al. Molecular aging of tau: disulfide-independent aggregation and non-enzymatic degradation in vitro and in vivo. J. Neurochem. 90, 1302–1311 (2004). The authors show that site-specific deamidation or isomerization and non-enzymatic degradation of ageing tau facilitates tau aggregation and can cause the smearing of PHFs on western blot that is typical of AD-tau. · DOI
  59. Ledesma, M. D., Bonay, P. & Avila, J. Tau protein from Alzheimer's disease patients is glycated at its tubulin-binding domain. J. Neurochem. 65, 1658–1664 (1995). · DOI · Paper page
  60. Reyes, J. F., Geula, C., Vana, L. & Binder, L. I. Selective tau tyrosine nitration in non-AD tauopathies. Acta Neuropathol. 123, 119–132 (2012). · DOI
  61. Funk, K. E. et al. Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity. Biochem. J. 462, 77–88 (2014). · DOI · Paper page
  62. Shimura, H., Schwartz, D., Gygi, S. P. & Kosik, K. S. CHIP–Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J. Biol. Chem. 279, 4869–4876 (2004). · DOI
  63. Babu, J. R., Geetha, T. & Wooten, M. W. Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J. Neurochem. 94, 192–203 (2005). · DOI · Paper page
  64. Nathan, J. A., Kim, H. T., Ting, L., Gygi, S. P. & Goldberg, A. L. Why do cellular proteins linked to K63-polyubiquitin chains not associate with proteasomes? EMBO J. 32, 552–565 (2013). · DOI
  65. Dorval, V. & Fraser, P. E. Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein. J. Biol. Chem. 281, 9919–9924 (2006). · DOI · Paper page
  66. Pountney, D. L. et al. SUMO-1 marks the nuclear inclusions in familial neuronal intranuclear inclusion disease. Exp. Neurol. 184, 436–446 (2003). · DOI
  67. Corsetti, V. et al. NH2-truncated human tau induces deregulated mitophagy in neurons by aberrant recruitment of Parkin and UCHL-1: implications in Alzheimer's disease. Hum. Mol. Genet. 24, 3058–3081 (2015). · DOI · Paper page
  68. Garg, S., Timm, T., Mandelkow, E. M., Mandelkow, E. & Wang, Y. Cleavage of Tau by calpain in Alzheimer's disease: the quest for the toxic 17 kD fragment. Neurobiol. Aging 32, 1–14 (2011). · DOI · Paper page
  69. Derisbourg, M. et al. Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms. Sci. Rep. 5, 9659 (2015). · DOI
  70. Drubin, D. G., Caput, D. & Kirschner, M. W. Studies on the expression of the microtubule-associated protein, tau, during mouse brain development, with newly isolated complementary DNA probes. J. Cell Biol. 98, 1090–1097 (1984). · DOI
  71. Litman, P., Barg, J., Rindzoonski, L. & Ginzburg, I. Subcellular localization of tau mRNA in differentiating neuronal cell culture: implications for neuronal polarity. Neuron 10, 627–638 (1993). · DOI
  72. Aronov, S., Aranda, G., Behar, L. & Ginzburg, I. Axonal tau mRNA localization coincides with tau protein in living neuronal cells and depends on axonal targeting signal. J. Neurosci. 21, 6577–6587 (2001). · DOI
  73. Morita, T. & Sobue, K. Specification of neuronal polarity regulated by local translation of CRMP2 and Tau via the mTOR–p70S6K pathway. J. Biol. Chem. 284, 27734–27745 (2009). · DOI
  74. Kosik, K. S., Crandall, J. E., Mufson, E. J. & Neve, R. L. Tau in situ hybridization in normal and Alzheimer brain: localization in the somatodendritic compartment. Ann. Neurol. 26, 352–361 (1989). · DOI
  75. Li, X. et al. Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration. EMBO J. 30, 4825–4837 (2011). This study identifies an axonal sorting mechanism of tau at the axonal initial segment. · DOI
  76. Feinstein, S. C. & Wilson, L. Inability of tau to properly regulate neuronal microtubule dynamics: a loss-of-function mechanism by which tau might mediate neuronal cell death. Biochim. Biophys. Acta 1739, 268–279 (2005). · DOI
  77. Mandelkow, E. M. & Mandelkow, E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb. Perspect. Med. 2, a006247 (2012). · DOI
  78. Stamer, K., Vogel, R., Thies, E., Mandelkow, E. & Mandelkow, E. M. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J. Cell Biol. 156, 1051–1063 (2002). · DOI · Paper page
  79. Vershinin, M., Carter, B. C., Razafsky, D. S., King, S. J. & Gross, S. P. Multiple-motor based transport and its regulation by Tau. Proc. Natl Acad. Sci. USA 104, 87–92 (2007). · DOI · Paper page
  80. Konzack, S., Thies, E., Marx, A., Mandelkow, E. M. & Mandelkow, E. Swimming against the tide: mobility of the microtubule-associated protein tau in neurons. J. Neurosci. 27, 9916–9927 (2007). · DOI
  81. Utton, M. A., Noble, W. J., Hill, J. E., Anderton, B. H. & Hanger, D. P. Molecular motors implicated in the axonal transport of tau and α-synuclein. J. Cell Sci. 118, 4645–4654 (2005). · DOI
  82. Kanaan, N. M. et al. Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. J. Neurosci. 31, 9858–9868 (2011). · DOI
  83. Magnani, E. et al. Interaction of tau protein with the dynactin complex. EMBO J. 26, 4546–4554 (2007). · DOI
  84. Yuan, A., Kumar, A., Peterhoff, C., Duff, K. & Nixon, R. A. Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. J. Neurosci. 28, 1682–1687 (2008). · DOI
  85. Caceres, A. & Kosik, K. S. Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons. Nature 343, 461–463 (1990). · DOI
  86. Knops, J. et al. Overexpression of tau in a nonneuronal cell induces long cellular processes. J. Cell Biol. 114, 725–733 (1991). · DOI · Paper page
  87. Dawson, H. N. et al. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J. Cell Sci. 114, 1179–1187 (2001). · DOI · Paper page
  88. Harada, A. et al. Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 369, 488–491 (1994). This study established the first tau-knockout transgenic mouse line and found that the deficiency of tau does not cause overt pathology, owing to the compensatory expression of MAP1A. · DOI
  89. Tai, H. C. et al. Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimer inverted question marks disease. Acta Neuropathol. Commun. 2, 146 (2014).
  90. Mondragon-Rodriguez, S. et al. Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-d-aspartate receptor-dependent tau phosphorylation. J. Biol. Chem. 287, 32040–32053 (2012). · DOI · Paper page
  91. Loomis, P. A., Howard, T. H., Castleberry, R. P. & Binder, L. I. Identification of nuclear tau isoforms in human neuroblastoma cells. Proc. Natl Acad. Sci. USA 87, 8422–8426 (1990). · DOI
  92. Fernandez-Nogales, M. et al. Huntington's disease is a four-repeat tauopathy with tau nuclear rods. Nat. Med. 20, 881–885 (2014). · DOI · Paper page
  93. Gheyara, A. L. et al. Tau reduction prevents disease in a mouse model of Dravet syndrome. Ann. Neurol. 76, 443–456 (2014). · DOI · Paper page
  94. Holth, J. K. et al. Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy. J. Neurosci. 33, 1651–1659 (2013). · DOI · Paper page
  95. DeVos, S. L. et al. Antisense reduction of tau in adult mice protects against seizures. J. Neurosci. 33, 12887–12897 (2013). This paper demonstrates that treatment with antisense oligonucleotides can reduce tau-induced pathology. · DOI · Paper page
  96. Lei, P. et al. Motor and cognitive deficits in aged tau knockout mice in two background strains. Mol. Neurodegener. 9, 29 (2014). · DOI · Paper page
  97. Hong, X. P. et al. Essential role of tau phosphorylation in adult hippocampal neurogenesis. Hippocampus 20, 1339–1349 (2010). · DOI
  98. Fuster-Matanzo, A. et al. Function of tau protein in adult newborn neurons. FEBS Lett. 583, 3063–3068 (2009). · DOI · Paper page
  99. Kimura, T. et al. Microtubule-associated protein tau is essential for long-term depression in the hippocampus. Phil. Trans. R. Soc. B 369, 20130144 (2014). · DOI · Paper page
  100. Ahmed, T. et al. Cognition and hippocampal synaptic plasticity in mice with a homozygous tau deletion. Neurobiol. Aging 35, 2474–2478 (2014). · DOI · Paper page
  101. Biernat, J. et al. Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Mol. Biol. Cell 13, 4013–4028 (2002). · DOI · Paper page
  102. Whiteman, I. T. et al. Activated actin-depolymerizing factor/cofilin sequesters phosphorylated microtubule-associated protein during the assembly of Alzheimer-like neuritic cytoskeletal striations. J. Neurosci. 29, 12994–13005 (2009). · DOI · Paper page
  103. Kouri, N. et al. Novel mutation in MAPT exon 13 (p. N410H) causes corticobasal degeneration. Acta Neuropathol. 127, 271–282 (2014). · DOI
  104. Coppola, G. et al. Evidence for a role of the rare p. A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum. Mol. Genet. 21, 3500–3512 (2012). · DOI · Paper page
  105. Barghorn, S. et al. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry 39, 11714–11721 (2000). · DOI
  106. Hong, M. et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282, 1914–1917 (1998). The authors demonstrate that FTDP-17 mutants of tau show reduced microtubule binding and accelerated aggregation. · DOI
  107. Jellinger, K. A. et al. PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol. 129, 757–762 (2015). · DOI · Paper page
  108. Braak, H. & Del Tredici, K. Are cases with tau pathology occurring in the absence of Aβ deposits part of the AD-related pathological process? Acta Neuropathol. 128, 767–772 (2014). · DOI
  109. von Bergen, M. et al. Assembly of τ protein into Alzheimer paired helical filaments depends on a local sequence motif (306VQIVYK311) forming β structure. Proc. Natl Acad. Sci. USA 97, 5129–5134 (2000). This study identifies two hexapeptide motifs (VQIINK and VQIVYK) in tau R2 and R3, with high propensity for β-sheet structure responsible for tau aggregation. · DOI · Paper page
  110. Sawaya, M. R. et al. Atomic structures of amyloid cross-β spines reveal varied steric zippers. Nature 447, 453–457 (2007). This paper reveals that 4–7-residue sequence motifs of neurodegenerative disease-related proteins, including tau, are sufficient to form fibrils composed of steric zippers, formed by two tightly interdigitated β-sheets. · DOI
  111. Khlistunova, I. et al. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J. Biol. Chem. 281, 1205–1214 (2006). · DOI
  112. Wille, H., Drewes, G., Biernat, J., Mandelkow, E. M. & Mandelkow, E. Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro. J. Cell Biol. 118, 573–584 (1992). · DOI
  113. Hernandez, F., Cuadros, R. & Avila, J. Zeta 14-3-3 protein favours the formation of human tau fibrillar polymers. Neurosci. Lett. 357, 143–146 (2004). · DOI
  114. Giustiniani, J. et al. Immunophilin FKBP52 induces Tau-P301L filamentous assembly in vitro and modulates its activity in a model of tauopathy. Proc. Natl Acad. Sci. USA 111, 4584–4589 (2014). · DOI
  115. Braak, E., Braak, H. & Mandelkow, E. M. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol. 87, 554–567 (1994). · DOI
  116. Alonso, A., Zaidi, T., Novak, M., Grundke-Iqbal, I. & Iqbal, K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc. Natl Acad. Sci. USA 98, 6923–6928 (2001). · DOI · Paper page
  117. Schneider, A., Biernat, J., von Bergen, M., Mandelkow, E. & Mandelkow, E. M. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 38, 3549–3558 (1999). · DOI · Paper page
  118. Tepper, K. et al. Oligomer formation of tau protein hyperphosphorylated in cells. J. Biol. Chem. 289, 34389–34407 (2014). · DOI
  119. Zilka, N. et al. Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett. 580, 3582–3588 (2006). · DOI
  120. Zhang, Z. et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease. Nat. Med. 20, 1254–1262 (2014). · DOI · Paper page
  121. Wang, Y. P., Biernat, J., Pickhardt, M., Mandelkow, E. & Mandelkow, E. M. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc. Natl Acad. Sci. USA 104, 10252–10257 (2007). The authors show that truncation of tau can accelerate its aggregation in cells and that pro-aggregant truncated tau can seed the aggregation of endogenous tau. · DOI
  122. Fatouros, C. et al. Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity. Hum. Mol. Genet. 21, 3587–3603 (2012). · DOI
  123. Clavaguera, F. et al. Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice. Acta Neuropathol. 127, 299–301 (2014). · DOI
  124. Sanders, D. W. et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271–1288 (2014). This paper shows that tau may form different prion-like strains, leading to distinct seeding and spreading pattern of tau pathology. · DOI · Paper page
  125. Zhukareva, V. et al. Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. Ann. Neurol. 49, 165–175 (2001). · DOI
  126. Spires-Jones, T. L. et al. In vivo imaging reveals dissociation between caspase activation and acute neuronal death in tangle-bearing neurons. J. Neurosci. 28, 862–867 (2008). · DOI · Paper page
  127. Santacruz, K. et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476–481 (2005). This study describes a regulatable transgenic mouse line of tauopathy, showing that switching off the expression of the transgenic human tau can rescue cognitive deficits despite the continuing presence of tau aggregates, and implying that tau aggregates are not sufficient for neurodegeneration. · DOI · Paper page
  128. Sydow, A. et al. Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. J. Neurosci. 31, 2511–2525 (2011). · DOI · Paper page
  129. Alonso Adel, C., Li, B., Grundke-Iqbal, I. & Iqbal, K. Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proc. Natl Acad. Sci. USA 103, 8864–8869 (2006). · DOI · Paper page
  130. Lasagna-Reeves, C. A. et al. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J. 26, 1946–1959 (2012). · DOI · Paper page
  131. Maeda, S. et al. Granular tau oligomers as intermediates of tau filaments. Biochemistry 46, 3856–3861 (2007). · DOI
  132. Tian, H. et al. Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations. Int. J. Cell Biol. 2013, 260787 (2013). · DOI · Paper page
  133. Flach, K. et al. Tau oligomers impair artificial membrane integrity and cellular viability. J. Biol. Chem. 287, 43223–43233 (2012). · DOI · Paper page
  134. Rizzu, P. et al. High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. Am. J. Hum. Genet. 64, 414–421 (1999). · DOI
  135. Mocanu, M. M. et al. The potential for β-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J. Neurosci. 28, 737–748 (2008). This paper demonstrates that the propensity for β-structure in one hexapeptide motif of pro-aggregant tau can cause neurodegeneration that can be reversed by blocking tau expression or by blocking aggregation using anti-aggregant tau. · DOI · Paper page
  136. Sarkar, M., Kuret, J. & Lee, G. Two motifs within the tau microtubule-binding domain mediate its association with the hsc70 molecular chaperone. J. Neurosci. Res. 86, 2763–2773 (2008). · DOI
  137. Guthrie, C. R., Schellenberg, G. D. & Kraemer, B. C. SUT-2 potentiates tau-induced neurotoxicity in Caenorhabditis elegans. Hum. Mol. Genet. 18, 1825–1838 (2009). · DOI
  138. Kraemer, B. C. & Schellenberg, G. D. SUT-1 enables tau-induced neurotoxicity in C. elegans. Hum. Mol. Genet. 16, 1959–1971 (2007). · DOI
  139. Seward, M. E. et al. Amyloid-β signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease. J. Cell Sci. 126, 1278–1286 (2013). · DOI
  140. Decker, J. M. et al. Pro-aggregant Tau impairs mossy fiber plasticity due to structural changes and Ca++ dysregulation. Acta Neuropathol. Commun. 3, 23 (2015). This paper demonstrates that tau pathology may cause presynaptic dysfunction at an early stage of neurodegeneration. · DOI
  141. Pooler, A. M., Phillips, E. C., Lau, D. H., Noble, W. & Hanger, D. P. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 14, 389–394 (2013). This study demonstrates that the physiological release of tau can be stimulated by neuronal activity. · DOI · Paper page
  142. Yamada, K. et al. Neuronal activity regulates extracellular tau in vivo. J. Exp. Med. 211, 387–393 (2014). · DOI
  143. Johnson, G. V. et al. The tau protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived fragments. J. Neurochem. 68, 430–433 (1997). · DOI · Paper page
  144. Yamada, K. et al. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J. Neurosci. 31, 13110–13117 (2011). This paper demonstrates the release of tau by neurons, arguing that extracellular tau may be in equilibrium with intracellular tau. · DOI · Paper page
  145. Karch, C. M., Jeng, A. T. & Goate, A. M. Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies. J. Biol. Chem. 287, 42751–42762 (2012). · DOI
  146. Nickel, W. & Rabouille, C. Mechanisms of regulated unconventional protein secretion. Nat. Rev. Mol. Cell Biol. 10, 148–155 (2009). · DOI
  147. Gomez-Ramos, A., Diaz-Hernandez, M., Rubio, A., Miras-Portugal, M. T. & Avila, J. Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells. Mol. Cell. Neurosci. 37, 673–681 (2008). · DOI
  148. Gomez-Ramos, A. et al. Characteristics and consequences of muscarinic receptor activation by tau protein. Eur. Neuropsychopharmacol. 19, 708–717 (2009). · DOI
  149. Braak, H. & Braak, E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol. 92, 197–201 (1996). · DOI · Paper page
  150. Nave, K. A. & Werner, H. B. Myelination of the nervous system: mechanisms and functions. Annu. Rev. Cell Dev. Biol. 30, 503–533 (2014). · DOI · Paper page
  151. Hochgrafe, K. et al. Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau. Acta Neuropathol. Commun. 3, 25 (2015). · DOI
  152. Wischik, C. M. et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. J. Alzheimers Dis. 44, 705–720 (2015). · DOI · Paper page
  153. Sievers, S. A. et al. Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. Nature 475, 96–100 (2011). This paper identifies several d-amino acid peptides that can inhibit tau aggregation by interacting with steric zippers formed by the hexapeptide. · DOI
  154. Brunden, K. R. et al. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J. Neurosci. 30, 13861–13866 (2010). · DOI · Paper page
  155. Blair, L. J., Sabbagh, J. J. & Dickey, C. A. Targeting Hsp90 and its co-chaperones to treat Alzheimer's disease. Expert Opin. Ther. Targets 18, 1219–1232 (2014). · DOI
  156. Kruger, U., Wang, Y., Kumar, S. & Mandelkow, E. M. Autophagic degradation of tau in primary neurons and its enhancement by trehalose. Neurobiol. Aging 33, 2291–2305 (2012). · DOI · Paper page
  157. Berger, Z. et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 15, 433–442 (2006). · DOI · Paper page
  158. Sigurdsson, E. M. Tau immunotherapy and imaging. Neurodegener. Dis. 13, 103–106 (2014). · DOI
  159. Golde, T. E. Open questions for Alzheimer's disease immunotherapy. Alzheimers Res. Ther. 6, 3 (2014). · DOI
  160. Congdon, E. E., Gu, J., Sait, H. B. & Sigurdsson, E. M. Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance. J. Biol. Chem. 288, 35452–35465 (2013). · DOI · Paper page
  161. Collin, L. et al. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease. Brain 137, 2834–2846 (2014). · DOI
  162. Yanamandra, K. et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402–414 (2013). This study presents a new concept of immunotherapy: targeting extracellular tau seeds with tau-specific antibodies to prevent the spreading of tau pathology. · DOI · Paper page
  163. Neve, R. L., Harris, P., Kosik, K. S., Kurnit, D. M. & Donlon, T. A. Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. Brain Res. 387, 271–280 (1986).
  164. Trabzuni, D. et al. MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies. Hum. Mol. Genet. 21, 4094–4103 (2012). · DOI · Paper page
  165. Boutajangout, A., Boom, A., Leroy, K. & Brion, J. P. Expression of tau mRNA and soluble tau isoforms in affected and non-affected brain areas in Alzheimer's disease. FEBS Lett. 576, 183–189 (2004). · DOI

Cited by

Sorted by citations

Metadata

Authors
Wang, Y., & Mandelkow, E.
Affiliations
Center of Advanced European Studies and Research (DE)
Corresponding author
Wang, Yipeng
ORCID
Wang, Yipeng
Venue
Nature Reviews Neuroscience
Publisher
Springer Science and Business Media LLC
Published
2015-12-03
Volume
17
Issue
1
Pages
22-35
ISSN
  • 1471-003X (ISSN-L)
  • 1471-0048
DOI
10.1038/nrn.2015.1
OpenAlex
W2185034389
Cited by
2,251
References
61
Citations by year
2026: 255 · 2025: 276 · 2024: 253 · 2023: 240 · 2022: 228 · 2021: 244 · 2020: 231 · 2019: 174 · 2018: 173 · 2017: 115 · 2016: 60
FWCI
14.18
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature reviews. Neuroscience (publishedVersion)
  • PubMed (publishedVersion)
  • DZNE Pub (submittedVersion)
  • MPG.PuRe (Max Planck Society) (submittedVersion)
Funders
Wellcome Trust
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
tau protein, microtubule stabilization, tauopathy, tau aggregation, neurodegeneration, post-translational modification, intrinsically disordered proteins, axon growth
MeSH terms
Animals, Humans, Phosphorylation, Protein Processing, Post-Translational, tau Proteins, Tauopathies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review